Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of rosuvastatin and atorvastatin on insulin resistance
IRCT20140514017686N2Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rosuvastatin and atorvastatin in type 2 diabetes mellitus (T2DM) and dyslipidemia (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoint: Change in insulin resistance. Started Sep 2022; status: completed.
02
Drugs
rosuvastatinatorvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on IRCT20140514017686N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140514017686N2.